Taletrectinib
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 43 publications
Comparative efficacy of taletrectinib versus first-generation TKIs in TKI-naïve ROS1+ non-small cell lung cancer: A matching-adjusted indirect comparison.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 15, 2026
Long-Term Efficacy and Safety of Taletrectinib in Patients With ROS1+ Non-Small Cell Lung Cancer: Results From the Phase II TRUST-I Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 21, 2026
Phototesting-Demonstrated Broad-Spectrum Ultraviolet Photosensitivity Induced by Taletrectinib.
Journal: The Journal of dermatology
Published: March 14, 2026
Properties of FDA-approved small molecule protein kinase inhibitors: A 2026 update.
Journal: Pharmacological research
Published: January 20, 2026
An evaluation of taletrectinib for the treatment of ROS1+ non-small cell lung cancer.
Journal: Expert review of anticancer therapy
Published: January 18, 2026
Next-Generation Targeted Therapy: The Evolving Role of Taletrectinib in Fusion-Positive Malignancies.
Journal: Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology
Published: December 09, 2025
Taletrectinib as an emerging therapy for ROS1-positive non-small cell lung cancer: findings from TRUST phase 2 trials.
Journal: Annals of medicine and surgery (2012)
Published: November 14, 2025
ROS1-positive non-small cell lung cancer: from genomics to treatment decisions.
Journal: Frontiers in oncology
Published: November 04, 2025
Targeting ROS1 in NSCLC: Clinical Advances and Future Directions of Taletrectinib.
Journal: Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology
Published: November 03, 2025
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; durvalumab, cemiplimab, zongertinib, and taletrectinib for lung cancer, pirtobrutinib and atezolizumab for lymphoma, durvalumab for bladder cancer, panitumumab plus sotorasib for colorectal cancer, and vorasidenib for glioma.
Journal: International journal of clinical oncology
Published: October 25, 2025
Evolving Therapeutic Landscape of ROS1-Positive Non-Small Cell Lung Cancer: An Updated Review.
Journal: Current oncology (Toronto, Ont.)
Published: October 15, 2025
Last Updated: 09/26/2026